• Humacyte secured FDA acceptance of its IND for a first-in-human study of its coronary tissue engineered vessel in CABG.
• Phase 2a trial set to start this quarter in 10 adult patients; primary patency check at two months, follow-up up to three years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270800PRIMZONEFULLFEED9788296) on July 27, 2026, and is solely responsible for the information contained therein.